An Ad26‐MVA‐BN‐based therapeutic vaccine targeting HPV16 and HPV18 related disease is immunogenic in preclinical models and in women with persistent HPV infections

Abstract Objectives To develop a therapeutic human papillomavirus (HPV) vaccine capable of intercepting HPV‐related cervical disease to reduce the number of new cancer cases and associated deaths. Methods We previously reported that replication‐deficient adenovirus type 26 and 35‐based vectors (Ad26...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Selina Khan, Satish Boedhoe, Miranda Baert, Jan Serroyen, Thierry Verbinnen, Ariane Volkmann, Markus Kalla, Katrin Weidner, Mathieu Le Gars, Jerry Sadoff, Michal Sarnecki, Jort Vellinga, Jerome Custers, Gert Scheper, Hanneke Schuitemaker, Roland Zahn
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2026-03-01
Edice:	Clinical & Translational Immunology
Témata:	adenoviral vector human papillomavirus modified vaccinia Ankara therapeutic vaccine
On-line přístup:	https://doi.org/10.1002/cti2.70089
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!